<DOC>
	<DOCNO>NCT01649050</DOCNO>
	<brief_summary>To evaluate efficacy safety BGG492 versus placebo moderate severe spasticity due multiple sclerosis</brief_summary>
	<brief_title>Efficacy 5 Weeks Treatment With BGG492 Patients With Spasticity Due Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Key Diagnosis multiple sclerosis ( MS ) type . MS diagnosis least 6 month prior screen . Stable MS relapse within 3 month prior screen . Treated untreated spasticity due MS least 3 month prior screen , wholly relieve antispasticity medication . Key exclusion criterion : Patients symptoms spasticity due MS . Patients take three different antispasticity medication . Acute MS exacerbation require treatment within 3 month Screening Visit . Initiation , discontinuation interferon beta disease modify therapy MS within 3 month Screening Visit . Use baclofen pump time . Wheelchair bedbound patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>